Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04. Oktober 2023 07:30 ET
|
Kura Oncology, Inc.
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors – SAN DIEGO, Oct. 04, 2023 ...
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
28. September 2023 07:30 ET
|
Kura Oncology, Inc.
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to include KRASG12C-mutant NSCLC in combination portion of Phase 1...
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
19. September 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
14. August 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2023 Financial Results
03. August 2023 16:05 ET
|
Kura Oncology, Inc.
– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and...
Kura Oncology to Report Second Quarter 2023 Financial Results
27. Juli 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
14. Juni 2023 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
13. Juni 2023 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
11. Juni 2023 03:45 ET
|
Kura Oncology, Inc.
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH...
Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress
30. Mai 2023 07:30 ET
|
Kura Oncology, Inc.
– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 – – Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral...